Generic Twynsta Availability
TWYNSTA (amlodipine besylate; telmisartan - tablet; oral)
Manufacturer: BOEHRINGER INGELHEIM
Approval date: October 16, 2009
Strength(s): EQ 10MG BASE;40MG, EQ 10MG BASE;80MG [RLD], EQ 5MG BASE;40MG, EQ 5MG BASE;80MG
Has a generic version of Twynsta been approved?
No. There is currently no therapeutically equivalent version of Twynsta available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Twynsta. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Benzimidazoles useful as angiotensin-11 antagonists
Issued: January 7, 1997
Inventor(s): Hauel; Norbert & Narr, deceased; Berthold & Ries; Uwe & van Meel; Jacobus C. A. & Wienen; Wolfgang & Entzeroth; Michael
Assignee(s): Dr. Karl Thomae GmbH
Disclosed herein are angiotensin-II antagonists of the formula ##STR1## wherein R.sub.1 is, other than hydrogen and, inter alia, halogen, lower alkyl or cycloalkyl; R.sub.2 is, inter alia, optionally substituted benzimidazol-2-yl, 5,6,7,8-tetrahydro-imidazo[1,2-a]pyridin-2-yl, butanesultam-1-yl, imidazol-4-yl, and tetrahydobenzimidazol-2-yl; R.sub.3 is, inter alia, lower alkyl; and, R.sub.4 is an acidic group, such as carboxyl or tetrazolyl. An exemplary compound is: (a) 4'-[[2-n-propyl-4-methyl-6-(1-methylbenzimidazole-2-yl)-benzimidazol-1-yl] methyl]-biphenyl-2-carboxylic acid.Patent expiration dates:
- January 7, 2014✓✓✓
- January 7, 2014
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- October 16, 2012 - NEW COMBINATION
- Twynsta Consumer Information (Drugs.com)
- Twynsta Consumer Information (Wolters Kluwer)
- Twynsta Consumer Information (Cerner Multum)
- Twynsta Advanced Consumer Information (Micromedex)
- Telmisartan/amlodipine Consumer Information (Wolters Kluwer)
- Amlodipine and telmisartan Consumer Information (Cerner Multum)
- Telmisartan and amlodipine Advanced Consumer Information (Micromedex)
|Drug Patent||A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.|
|Drug Exclusivity||Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.|
|RLD||A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.|